We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+12.8%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.21B
AUM Growth
-$296M
(-8.4%)
Cap. Flow
-$592M
Cap. Flow
% of AUM
-18.42%
Top 10 Holdings %
Top 10 Hldgs %
43.24%
Holding
304
New
89
Increased
36
Reduced
82
Closed
88
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtaiBeckley Inc
ATAI
|
+$25.3M |
| 2 |
Agilon Health
AGL
|
+$13.5M |
| 3 |
Eli Lilly
LLY
|
+$13.2M |
| 4 |
Privia Health
PRVA
|
+$12.8M |
| 5 |
Lantheus
LNTH
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$23.9M |
| 2 |
Vericel Corp
VCEL
|
+$20.8M |
| 3 |
Align Technology
ALGN
|
+$19M |
| 4 |
SI-BONE Inc
SIBN
|
+$17.5M |
| 5 |
STAAR Surgical
STAA
|
+$14.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.64% |
| 2 | Industrials | 1.41% |
| 3 | Materials | 0.54% |
| 4 | Financials | 0.48% |
| 5 | Consumer Staples | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Forte Biosciences
FBRX
$1.58B
| $2.21M | 0.07% |
2,623
-1,916
| -42% | -$1.73M |
|
|
FRONU
152
DELISTED
Frontier Acquisition Corp. Units
FRONU
| $2.17M | 0.07% |
216,708
-83,292
| -28% | -$838K |
|
|
FVAM
153
DELISTED
5:01 Acquisition Corp
FVAM
| $2.15M | 0.07% |
215,836
-3,300
| -2% | -$33.1K |
|
|
VERO
154
DELISTED
Venus Concept
VERO
| $2.14M | 0.07% |
4,163
-88
| -2% | -$31.7K |
|
155
Novavax
NVAX
$1.31B
| $2.12M | 0.07% |
+10,000
| New | +$1.83M |
|
156
Nautilus Biotechnolgy
NAUT
$113M
| $2.09M | 0.07% |
207,079
-88,475
| -30% | -$958K |
|
157
Kura Oncology
KURA
$882M
| $2.08M | 0.06% |
99,862
-24,378
| -20% | -$605K |
|
158
CALL
Compugen
CGEN
$221M
| $2.06M | 0.06% |
248,800
+50,400
| +25% | +$409K |
|
159
Cyclerion Therapeutics
CYCN
$16.7M
| $1.98M | 0.06% |
+25,374
| New | +$1.59M |
|
160
Greenlane Holdings
GNLN
$1.24M
| – | – |
0
| – | – |
|
|
161
PUT
Compugen
CGEN
$221M
| $1.61M | 0.05% |
+194,900
| New | +$1.58M |
|
|
PMGMU
162
DELISTED
Priveterra Acquisition Corp. Units
PMGMU
| $1.61M | 0.05% |
161,472
-50,000
| -24% | -$498K |
|
|
RPTX
163
DELISTED
Repare Therapeutics
RPTX
| $1.6M | 0.05% |
51,271
-2,369
| -4% | -$77.6K |
|
164
Travere Therapeutics
TVTX
$5.68B
| $1.54M | 0.05% |
105,382
-21,151
| -17% | -$417K |
|
165
Phathom Pharmaceuticals
PHAT
$688M
| $1.53M | 0.05% |
45,211
-18,561
| -29% | -$665K |
|
|
RCOR
166
DELISTED
Renovacor, Inc.
RCOR
| $1.53M | 0.05% |
153,960
| – | – |
|
|
SRRA
167
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.46M | 0.05% |
74,967
-2,296
| -3% | -$41.7K |
|
|
VXRT
168
CALL
DELISTED
Vaxart
VXRT
| $1.46M | 0.05% |
194,500
-207,000
| -52% | -$1.45M |
|
|
PSTX
169
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $1.43M | 0.04% |
143,120
-93,191
| -39% | -$834K |
|
170
CALL
Lexicon Pharmaceuticals
LXRX
$1.08B
| $1.38M | 0.04% |
+300,900
| New | +$1.45M |
|
|
AVDL
171
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.31M | 0.04% |
+195,200
| New | +$1.55M |
|
|
AVDL
172
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.19M | 0.04% |
176,206
-57,916
| -25% | -$460K |
|
173
Tango Therapeutics
TNGX
$4.44B
| $1.13M | 0.04% |
+98,921
| New | +$1.11M |
|
|
CMPS
174
CALL
Compass Pathways
CMPS
$1.85B
| $1.12M | 0.03% |
29,300
-700
| -2% | -$25K |
|
|
EPIX
175
DELISTED
ESSA Pharma
EPIX
| $1.11M | 0.03% |
38,803
-93,680
| -71% | -$2.72M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q2 2021 Portfolio in Review
As of Q2 2021, Pura Vida Investments held 304 positions worth $3.21B, down 8.4% from $3.51B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Pura Vida Investments withdrew a net $592M in Q2 2021, closing 88 positions and reducing 82 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $23.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.
Against the trend, Pura Vida Investments opened a new position in AtaiBeckley Inc worth $23.2M.
- Pura Vida Investments's largest Q2 2021 buy was AtaiBeckley Inc: 1,371,824 shares worth $23.2M.
- Pura Vida Investments added most to Quotient Limited Ordinary Shares in Q2 2021, an estimated $9.15M increase.
- Pura Vida Investments's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $14.6M.
- Pura Vida Investments fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $23.9M.
- Pura Vida Investments's ten largest holdings make up 43% of its $3.21B portfolio in Q2 2021.
- Pura Vida Investments opened 89 new positions and closed 88 in Q2 2021.
- Pura Vida Investments's portfolio value fell 8.4% quarter-over-quarter to $3.21B.
Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.